Aspirin and eicosapentaenoic acid may arrest progressive IgA nephropathy: A potential alternative to immunosuppression

Junichi Hirahashi; Norio Hanafusa; Takehiko Wada; Makoto Arita; Keiichi Hishikawa; Matsuhiko Hayashi; Masaomi Nangaku

doi:10.2169/internalmedicine.54.4623

Aspirin and eicosapentaenoic acid may arrest progressive IgA nephropathy: A potential alternative to immunosuppression

Junichi Hirahashi, Norio Hanafusa, Takehiko Wada, Makoto Arita, Keiichi Hishikawa, Matsuhiko Hayashi, Masaomi Nangaku

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

Abstract

Immunoglobulin (Ig) A nephropathy is a prevalent form of primary glomerulonephritis, which leads to end-stage renal failure in a significant proportion of patients. Immunotherapy, including steroid use, is widely used to induce disease remission; however, it can cause serious side effects. We herein report 3 cases of progressive IgA nephropathy and their successful treatment with a combination of aspirin and eicosapentaenoic acid (EPA) without the use of steroids. The precise mechanism responsible for the combination therapy is still unknown; however, aspirin may potentiate the production of anti-inflammatory lipid mediators derived from EPA. Further clinical trials are required to substantiate this treatment regimen.

Original language	English
Pages (from-to)	2377-2382
Number of pages	6
Journal	Internal Medicine
Volume	54
Issue number	18
DOIs	https://doi.org/10.2169/internalmedicine.54.4623
Publication status	Published - 2015 Sept 15

Keywords

Aspirin
Eicosapentaenoic acid
IgA nephropathy
Steroids

ASJC Scopus subject areas

Internal Medicine

Access to Document

10.2169/internalmedicine.54.4623

Cite this

@article{959feed6be434697804577bbabd4e58d,

title = "Aspirin and eicosapentaenoic acid may arrest progressive IgA nephropathy: A potential alternative to immunosuppression",

abstract = "Immunoglobulin (Ig) A nephropathy is a prevalent form of primary glomerulonephritis, which leads to end-stage renal failure in a significant proportion of patients. Immunotherapy, including steroid use, is widely used to induce disease remission; however, it can cause serious side effects. We herein report 3 cases of progressive IgA nephropathy and their successful treatment with a combination of aspirin and eicosapentaenoic acid (EPA) without the use of steroids. The precise mechanism responsible for the combination therapy is still unknown; however, aspirin may potentiate the production of anti-inflammatory lipid mediators derived from EPA. Further clinical trials are required to substantiate this treatment regimen.",

keywords = "Aspirin, Eicosapentaenoic acid, IgA nephropathy, Steroids",

author = "Junichi Hirahashi and Norio Hanafusa and Takehiko Wada and Makoto Arita and Keiichi Hishikawa and Matsuhiko Hayashi and Masaomi Nangaku",

note = "Publisher Copyright: {\textcopyright} 2015 The Japanese Society of Internal Medicine.",

year = "2015",

month = sep,

day = "15",

doi = "10.2169/internalmedicine.54.4623",

language = "English",

volume = "54",

pages = "2377--2382",

journal = "Internal Medicine",

issn = "0918-2918",

publisher = "Japanese Society of Internal Medicine",

number = "18",

}

TY - JOUR

T1 - Aspirin and eicosapentaenoic acid may arrest progressive IgA nephropathy

T2 - A potential alternative to immunosuppression

AU - Hirahashi, Junichi

AU - Hanafusa, Norio

AU - Wada, Takehiko

AU - Arita, Makoto

AU - Hishikawa, Keiichi

AU - Hayashi, Matsuhiko

AU - Nangaku, Masaomi

PY - 2015/9/15

Y1 - 2015/9/15

N2 - Immunoglobulin (Ig) A nephropathy is a prevalent form of primary glomerulonephritis, which leads to end-stage renal failure in a significant proportion of patients. Immunotherapy, including steroid use, is widely used to induce disease remission; however, it can cause serious side effects. We herein report 3 cases of progressive IgA nephropathy and their successful treatment with a combination of aspirin and eicosapentaenoic acid (EPA) without the use of steroids. The precise mechanism responsible for the combination therapy is still unknown; however, aspirin may potentiate the production of anti-inflammatory lipid mediators derived from EPA. Further clinical trials are required to substantiate this treatment regimen.

AB - Immunoglobulin (Ig) A nephropathy is a prevalent form of primary glomerulonephritis, which leads to end-stage renal failure in a significant proportion of patients. Immunotherapy, including steroid use, is widely used to induce disease remission; however, it can cause serious side effects. We herein report 3 cases of progressive IgA nephropathy and their successful treatment with a combination of aspirin and eicosapentaenoic acid (EPA) without the use of steroids. The precise mechanism responsible for the combination therapy is still unknown; however, aspirin may potentiate the production of anti-inflammatory lipid mediators derived from EPA. Further clinical trials are required to substantiate this treatment regimen.

KW - Aspirin

KW - Eicosapentaenoic acid

KW - IgA nephropathy

KW - Steroids

UR - http://www.scopus.com/inward/record.url?scp=84941584496&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941584496&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.54.4623

DO - 10.2169/internalmedicine.54.4623

M3 - Article

C2 - 26370865

AN - SCOPUS:84941584496

SN - 0918-2918

VL - 54

SP - 2377

EP - 2382

JO - Internal Medicine

JF - Internal Medicine

IS - 18

ER -

Aspirin and eicosapentaenoic acid may arrest progressive IgA nephropathy: A potential alternative to immunosuppression

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this